{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:41Z","timestamp":1790351441238,"version":"4.1.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T00:00:00Z","timestamp":1395705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>On March 27, 2013, a conditional marketing authorization valid throughout the European Union was issued for bosutinib (Bosulif) for the treatment of adult patients with chronic-phase, accelerated-phase, and blast-phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) previously treated with one tyrosine kinase inhibitor or more and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options. Bosutinib is a kinase inhibitor that targets the BCR-ABL kinase. The recommended dose is 500 mg of bosutinib once daily. The main evidence of efficacy for bosutinib was based on a CML subgroup analysis of study 3160A4-200, a phase I\/II study of bosutinib in Ph+ leukemia in imatinib-resistant or intolerant CML. The subgroup was defined based on the presence of a BCR-ABL kinase domain mutation that would be expected to confer resistance to dasatinib (F317, E255) or nilotinib (E255, Y253, F359) and expected to have sensitivity to bosutinib or based on the presence of medical conditions or prior toxicities that may predispose the patient to unacceptable risk in the setting of nilotinib or dasatinib therapy. A conditional marketing authorization was granted because of the limited evidence of efficacy and safety currently supporting this last-line indication.<\/jats:p>","DOI":"10.1634\/theoncologist.2013-0294","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T02:51:25Z","timestamp":1395802285000},"page":"421-425","source":"Crossref","is-referenced-by-count":11,"title":["The European Medicines Agency Review of Bosutinib for the Treatment of Adult Patients With Chronic Myelogenous Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use"],"prefix":"10.1093","volume":"19","author":[{"given":"Zahra","family":"Hanaizi","sequence":"first","affiliation":[{"name":"European Medicines Agency, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Unkrig","sequence":"additional","affiliation":[{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Enzmann","sequence":"additional","affiliation":[{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Camarero","sequence":"additional","affiliation":[{"name":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios, Servicio de Farmacolog\u00eda Cl\u00ednica, Hospital Puerta de Hierro, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Sancho-Lopez","sequence":"additional","affiliation":[{"name":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios, Servicio de Farmacolog\u00eda Cl\u00ednica, Hospital Puerta de Hierro, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Salmonson","sequence":"additional","affiliation":[{"name":"L\u00e4kemedelsverket, Medical Products Agency, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Laane","sequence":"additional","affiliation":[{"name":"North Estonia Regional Hospital, Tallinn, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pignatti","sequence":"additional","affiliation":[{"name":"European Medicines Agency, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,3,25]]},"reference":[{"key":"2021122308460455200_B1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"2021122308460455200_B2","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"2021122308460455200_B3","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"2021122308460455200_B4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021122308460455200_B5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"key":"2021122308460455200_B6","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23338","article-title":"Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors","volume":"87","author":"Redaelli","year":"2012","journal-title":"Am J Hematol"},{"key":"2021122308460455200_B7","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"2021122308460455200_B8","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"2021122308460455200_B9","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2013-0294","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0294","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/4\/421\/41861327\/oncolo_19_4_421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/4\/421\/41861327\/oncolo_19_4_421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T01:27:13Z","timestamp":1640309233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/4\/421\/6399522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,25]]},"references-count":9,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,3,25]]},"published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0294","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,4,1]]},"published":{"date-parts":[[2014,3,25]]}}}